MX2011007678A - Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa. - Google Patents

Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa.

Info

Publication number
MX2011007678A
MX2011007678A MX2011007678A MX2011007678A MX2011007678A MX 2011007678 A MX2011007678 A MX 2011007678A MX 2011007678 A MX2011007678 A MX 2011007678A MX 2011007678 A MX2011007678 A MX 2011007678A MX 2011007678 A MX2011007678 A MX 2011007678A
Authority
MX
Mexico
Prior art keywords
moderate
disease
alleviating
methods
symptoms associated
Prior art date
Application number
MX2011007678A
Other languages
English (en)
Inventor
Marc Cantillon
Susan B Huyck
Kenneth P Wolski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2011007678A publication Critical patent/MX2011007678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee un método para aliviar complicaciones motoras e indicaciones motoras en un paciente que padece de enfermedad de Parkinson de moderada a severa al administrar una composición que provee una cantidad efectiva del compuesto de fórmula I.
MX2011007678A 2009-01-20 2010-01-13 Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa. MX2011007678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14586709P 2009-01-20 2009-01-20
PCT/US2010/000063 WO2010085317A1 (en) 2009-01-20 2010-01-13 Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease

Publications (1)

Publication Number Publication Date
MX2011007678A true MX2011007678A (es) 2011-08-08

Family

ID=42041568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007678A MX2011007678A (es) 2009-01-20 2010-01-13 Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa.

Country Status (7)

Country Link
US (1) US20120053182A1 (es)
EP (1) EP2389175A1 (es)
AU (1) AU2010207004A1 (es)
CA (1) CA2750265A1 (es)
MX (1) MX2011007678A (es)
TW (1) TW201040190A (es)
WO (1) WO2010085317A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132006A (en) 2000-05-26 2007-09-28 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
BR0306919A (pt) * 2002-01-28 2004-11-09 Kyowa Hakko Kogyo Kk Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
EP2258372B8 (en) * 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders

Also Published As

Publication number Publication date
CA2750265A1 (en) 2010-07-29
WO2010085317A1 (en) 2010-07-29
EP2389175A1 (en) 2011-11-30
US20120053182A1 (en) 2012-03-01
AU2010207004A1 (en) 2011-07-28
TW201040190A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
WO2012015758A3 (en) Methods of treating pain
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MY158504A (en) Fatty acid niacin conjugates and their uses
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
MX2009010132A (es) Analogos de pirazolopirimidina y su uso como inhibidores de cinasa mtor y cinasa pi3.
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
WO2010080756A3 (en) Harmine derivatives for reducing body weight
MX377157B (es) Preparación para usarse en el tratamiento de un cáncer positivo de gd2.
WO2007143607A3 (en) Method of treating atrophic vaginitis
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
IN2012DN00639A (es)
MX342257B (es) Derivados y análogos de oxaspiro [2.5] octano.
MX2009005649A (es) Tratamiento para mieloma multiple.
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
GB2477256A (en) Medicament and method of diagnosis
BR112012008310A2 (pt) métodos para tratamento de tumores cerebrais
MX359125B (es) Método para fabricar una composición que comprende un anestésico local, un heparinoide y un regulador de ph.
MX2012010084A (es) Compuestos utiles para tratar transtornos neurodegenerativos.
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
MX2010004814A (es) Metodos para tratar esclerodermia.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MERCK SHARP & DOHME CORP.*

FA Abandonment or withdrawal